NLRP3 and atrial fibrillation: MCC950, a selective NLRP3 inhibitor, has been effective in reducing pro-inflammatory cytokine release in animal studies of both AF and PH, underscoring the importance of specifically targeting the NLRP3 pathway to address chronic inflammation [102,157,158].